

## Astellas transfers three products in Asia region to Daiichi Sankyo

17 October 2019 | News

**After closing of the agreement, Astellas will work closely with Daiichi Sankyo to ensure smooth transfer of the Products to continue stable delivery to patients**



Astellas Pharma Inc. has announced that subsidiaries of Astellas will transfer their marketing authorizations, trademark, and related contracts for “Nasea (5HT<sub>3</sub> receptor antagonist-type antiemetic)”, “Perdipine (calcium channel blocker)”, and “Oldeca (sustained release calcium antagonist)” (the “Products”) in Korea, Thailand, the Philippines, Indonesia, China and Taiwan to Daiichi Sankyo Co., Ltd. under an Asset Purchase Agreement concluded between both parties. Closing of the agreement is scheduled in third quarter of the fiscal year 2019.

After closing of the agreement, Astellas will work closely with Daiichi Sankyo to ensure smooth transfer of the Products to continue stable delivery to patients.

Marketing authorization of the Products in Japan, supply business of active ingredients/bulk to third parties in and outside of Japan, as well as the royalty business in Japan has been previously transferred to LTL Pharma Co., Ltd., under the Asset Purchase Agreement in 2017.

The agreement is a part of Astellas’ ongoing efforts to improve the quality and efficiency of operations and to optimize its cost structure so as to accommodate the rapidly changing business environment and achieve sustainable growth. Astellas will further expand their business in Asia region through optimization of resource allocation.

The total net sales of Astellas Pharma's three products in fiscal year 2018 were approximately 5.0 billion yen.

Daiichi Sankyo will take over the rights and obligations, including manufacturing and marketing approvals, for each of the products, and from December 2019 onwards, the manufacturer, LTL Pharma Co., Ltd., will supply them for sale in Asia by Daiichi Sankyo’s local subsidiaries and other companies.

Daiichi Sankyo will pay 9.6 billion yen to Astellas Pharma for the products to be taken over; moreover, in order to ensure

continuous supplies of the products to patients, both companies will cooperate to smoothly transfer manufacturing and marketing approvals in the targeted countries.

Daiichi Sankyo is strengthening its presence in each region by providing a rich range of regional value products in line with the market characteristics in each region, and the company strengthens its presence in Asia and plans to further contribute to healthcare in the region by acquiring these products.